Management of Dualsystems Biotech AG


Dr. Paul Helbling

dualsystems-biotech-ag-dr-paul-helbling-ceoPaul Helbling- CEO Dualsystems Biotech AG - LinkedIn

Dr. Paul Helbling, did his Master’s degree in Biology at the University of Zurich, and obtained his PhD in Developmental Biology at the Swiss Federal Institute of Technology (ETH) in Zurich. After his PhD he worked at the Foundation for Cardiovascular Research and organized clinical studies according to GCP. He moved on to MDS Pharma Services where he held various positions in the GLP compliant facilities, finally responsible for the ligand binding group that specialized in the analysis of biologics and anti-drug antibodies. His next position was in business development at the GMP compliant facilities of Solvias AG, responsible for southern Europe and Germany and opening new market territories in Turkey. He then became Head of Business Development at IBR Inc. a GLP-compliant service provider specialising in cell-based assays. Finally, he joined the team at Dualsystems as CEO that is focusing on identifying targets and off-targets on the living cells using LC-MS/MS.

Paul Helbling is fully responsible for the daily management of Dualsystems, reporting to the Board of Directors.



Board of Directors of Dualsystems Biotech AG

Dr. Raymond Bisang, President

Dr. Raymond Bisang, PresidentRaymond Bisang is a co-founder of Dualsystems. He is a senior partner of the law firm Suhr Würgler Maag Bisang in Zürich. He graduated from the University of Zürich and was a district judge before becoming an attorney at law in 1987. Besides the occupation within his law firm and Dualsystems, he holds board positions at a number of other companies in the fields of life science and finance.

Professor Dr. Michael Hottiger, Vice President

Professor Dr. Michael Hottiger, Vice PresidentMichael O. Hottiger (Prof. et Phil.II) is a co-founder of Dualsystems Biotech AG. He is a full professor of Molecular Biology at the Institute of Veterinary Biochemistry and Molecular Biology at the University of Zurich where he studied Veterinary Medicine and Molecular Biology. He then moved to the Howard Hughes Medical Institute at the University of Michigan (Ann Arbor, USA), before accepting a position as Principal Investigator at the University of Zurich in 1998. In 2001, he received the Doctor Ernst Th. Jucker Award and in 2004 the Phoenix Pharmazie-Wissenschaftspreis. Research in Michael’s group is focused on the molecular mechanisms of NF-kappaB-dependent gene expression during inflammation.

Dr. Jan zur Hausen

Dr. Jan zur HausenJan zur Hausen joined the board of directors of Dualsystems in 2010. He is managing director of Bergmann zur Hausen & Cie. GmbH, a corporate finance firm specialising in the healthcare industry. Previously he was senior vice president and Head of Healthcare Investment Banking at Sal. Oppenheim jr. & Cie. KGaA. Before that, he was a partner in the life science team of DVC (Deutsche Venture Capital) and is, until now, a member of the executive board of Mulligan BioCapital AG, where he is responsible for building and managing a portfolio of European and US life science companies. His curriculum also includes positions at MPM Capital, a US based venture capital firm and at Hoffmann-La Roche in Basel and Nutley, NJ. Jan did his undergraduate work at the University of Hohenheim and received a Ph.D. from the University of Basel.